Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Cash from Investing Activities (2020 - 2025)

Historic Cash from Investing Activities for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to $83000.0.

  • Vivos Therapeutics' Cash from Investing Activities rose 14322.92% to $83000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.1 million, marking a year-over-year decrease of 97570.42%. This contributed to the annual value of -$568000.0 for FY2024, which is 3341.15% up from last year.
  • According to the latest figures from Q3 2025, Vivos Therapeutics' Cash from Investing Activities is $83000.0, which was up 14322.92% from -$5.9 million recorded in Q2 2025.
  • In the past 5 years, Vivos Therapeutics' Cash from Investing Activities ranged from a high of $83000.0 in Q3 2025 and a low of -$5.9 million during Q2 2025
  • Over the past 5 years, Vivos Therapeutics' median Cash from Investing Activities value was -$192000.0 (recorded in 2024), while the average stood at -$573578.9.
  • In the last 5 years, Vivos Therapeutics' Cash from Investing Activities plummeted by 1953347.43% in 2021 and then soared by 14322.92% in 2025.
  • Quarter analysis of 5 years shows Vivos Therapeutics' Cash from Investing Activities stood at -$382000.0 in 2021, then soared by 47.64% to -$200000.0 in 2022, then grew by 17.5% to -$165000.0 in 2023, then changed by 0.0% to -$165000.0 in 2024, then skyrocketed by 150.3% to $83000.0 in 2025.
  • Its last three reported values are $83000.0 in Q3 2025, -$5.9 million for Q2 2025, and -$122000.0 during Q1 2025.